vs
Side-by-side financial comparison of INTEGRA LIFESCIENCES HOLDINGS CORP (IART) and STANDEX INTERNATIONAL CORP (SXI). Click either name above to swap in a different company.
INTEGRA LIFESCIENCES HOLDINGS CORP is the larger business by last-quarter revenue ($434.9M vs $221.3M, roughly 2.0× STANDEX INTERNATIONAL CORP). On growth, STANDEX INTERNATIONAL CORP posted the faster year-over-year revenue change (16.6% vs -1.7%). STANDEX INTERNATIONAL CORP produced more free cash flow last quarter ($12.9M vs $-5.4M). Over the past eight quarters, STANDEX INTERNATIONAL CORP's revenue compounded faster (11.7% CAGR vs 8.6%).
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
Standex International Corporation is a multi-industry manufacturer in five broad business segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions with operations in the United States, Europe, Canada, Japan, Singapore, Mexico, Turkey, India, and China. Headquartered in Salem, New Hampshire. Standex is divided into 12 units and 5 reporting segments. The company was incorporated in 1955 and contains multiple subsidiaries including Bakers Pride and Standex ...
IART vs SXI — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $434.9M | $221.3M |
| Net Profit | — | $2.1M |
| Gross Margin | 50.8% | 41.7% |
| Operating Margin | 5.3% | 16.1% |
| Net Margin | — | 1.0% |
| Revenue YoY | -1.7% | 16.6% |
| Net Profit YoY | — | 147.4% |
| EPS (diluted) | $-0.03 | $0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $434.9M | $221.3M | ||
| Q3 25 | $402.1M | $217.4M | ||
| Q2 25 | $415.6M | $222.0M | ||
| Q1 25 | $382.7M | $207.8M | ||
| Q4 24 | $442.6M | $189.8M | ||
| Q3 24 | $380.8M | $170.5M | ||
| Q2 24 | $418.2M | $180.2M | ||
| Q1 24 | $368.9M | $177.3M |
| Q4 25 | — | $2.1M | ||
| Q3 25 | $-5.4M | $15.1M | ||
| Q2 25 | $-484.1M | $14.8M | ||
| Q1 25 | $-25.3M | $21.9M | ||
| Q4 24 | — | $857.0K | ||
| Q3 24 | $-10.7M | $18.2M | ||
| Q2 24 | $-12.4M | $19.6M | ||
| Q1 24 | $-3.3M | $15.8M |
| Q4 25 | 50.8% | 41.7% | ||
| Q3 25 | 51.5% | 41.6% | ||
| Q2 25 | 50.4% | 41.1% | ||
| Q1 25 | 50.8% | 39.7% | ||
| Q4 24 | 56.3% | 37.6% | ||
| Q3 24 | 52.6% | 41.1% | ||
| Q2 24 | 54.0% | 38.5% | ||
| Q1 24 | 56.1% | 38.5% |
| Q4 25 | 5.3% | 16.1% | ||
| Q3 25 | 2.9% | 13.6% | ||
| Q2 25 | -123.4% | 15.6% | ||
| Q1 25 | -4.0% | 12.6% | ||
| Q4 24 | 8.0% | 4.5% | ||
| Q3 24 | -2.1% | 14.1% | ||
| Q2 24 | -0.7% | 15.1% | ||
| Q1 24 | 1.1% | 12.3% |
| Q4 25 | — | 1.0% | ||
| Q3 25 | -1.3% | 6.9% | ||
| Q2 25 | -116.5% | 6.7% | ||
| Q1 25 | -6.6% | 10.5% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | -2.8% | 10.7% | ||
| Q2 24 | -3.0% | 10.9% | ||
| Q1 24 | -0.9% | 8.9% |
| Q4 25 | $-0.03 | $0.17 | ||
| Q3 25 | $-0.07 | $1.25 | ||
| Q2 25 | $-6.31 | $1.23 | ||
| Q1 25 | $-0.33 | $1.81 | ||
| Q4 24 | $0.25 | $0.07 | ||
| Q3 24 | $-0.14 | $1.53 | ||
| Q2 24 | $-0.16 | $1.64 | ||
| Q1 24 | $-0.04 | $1.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $263.7M | $97.0M |
| Total DebtLower is stronger | $726.6M | $534.7M |
| Stockholders' EquityBook value | $1.0B | $700.2M |
| Total Assets | $3.6B | $1.6B |
| Debt / EquityLower = less leverage | 0.70× | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $263.7M | $97.0M | ||
| Q3 25 | $267.9M | $98.7M | ||
| Q2 25 | $253.6M | $104.5M | ||
| Q1 25 | $273.3M | $109.8M | ||
| Q4 24 | $273.6M | $121.1M | ||
| Q3 24 | $277.6M | $164.6M | ||
| Q2 24 | $296.9M | $154.2M | ||
| Q1 24 | $663.1M | $138.8M |
| Q4 25 | $726.6M | $534.7M | ||
| Q3 25 | $736.3M | $544.6M | ||
| Q2 25 | $745.9M | $552.5M | ||
| Q1 25 | $755.6M | $579.4M | ||
| Q4 24 | $760.5M | $534.3M | ||
| Q3 24 | $765.3M | $149.0M | ||
| Q2 24 | $770.2M | $148.9M | ||
| Q1 24 | $775.0M | $148.8M |
| Q4 25 | $1.0B | $700.2M | ||
| Q3 25 | $1.0B | $707.7M | ||
| Q2 25 | $1.0B | $711.7M | ||
| Q1 25 | $1.5B | $686.9M | ||
| Q4 24 | $1.5B | $656.0M | ||
| Q3 24 | $1.5B | $658.0M | ||
| Q2 24 | $1.5B | $621.5M | ||
| Q1 24 | $1.6B | $619.0M |
| Q4 25 | $3.6B | $1.6B | ||
| Q3 25 | $3.6B | $1.6B | ||
| Q2 25 | $3.7B | $1.6B | ||
| Q1 25 | $4.1B | $1.6B | ||
| Q4 24 | $4.0B | $1.5B | ||
| Q3 24 | $4.1B | $1.0B | ||
| Q2 24 | $4.1B | $1.0B | ||
| Q1 24 | $4.1B | $993.5M |
| Q4 25 | 0.70× | 0.76× | ||
| Q3 25 | 0.71× | 0.77× | ||
| Q2 25 | 0.72× | 0.78× | ||
| Q1 25 | 0.50× | 0.84× | ||
| Q4 24 | 0.49× | 0.81× | ||
| Q3 24 | 0.50× | 0.23× | ||
| Q2 24 | 0.50× | 0.24× | ||
| Q1 24 | 0.48× | 0.24× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.8M | $20.6M |
| Free Cash FlowOCF − Capex | $-5.4M | $12.9M |
| FCF MarginFCF / Revenue | -1.2% | 5.8% |
| Capex IntensityCapex / Revenue | 4.0% | 3.5% |
| Cash ConversionOCF / Net Profit | — | 9.70× |
| TTM Free Cash FlowTrailing 4 quarters | $-31.1M | $51.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.8M | $20.6M | ||
| Q3 25 | $40.9M | $16.8M | ||
| Q2 25 | $8.9M | $33.4M | ||
| Q1 25 | $-11.3M | $9.5M | ||
| Q4 24 | $50.7M | $9.1M | ||
| Q3 24 | $22.5M | $17.6M | ||
| Q2 24 | $40.4M | $28.5M | ||
| Q1 24 | $15.8M | $24.4M |
| Q4 25 | $-5.4M | $12.9M | ||
| Q3 25 | $25.8M | $10.4M | ||
| Q2 25 | $-11.2M | $24.8M | ||
| Q1 25 | $-40.2M | $3.5M | ||
| Q4 24 | $21.1M | $2.1M | ||
| Q3 24 | $-7.2M | $10.8M | ||
| Q2 24 | $10.7M | $22.0M | ||
| Q1 24 | $291.0K | $19.2M |
| Q4 25 | -1.2% | 5.8% | ||
| Q3 25 | 6.4% | 4.8% | ||
| Q2 25 | -2.7% | 11.2% | ||
| Q1 25 | -10.5% | 1.7% | ||
| Q4 24 | 4.8% | 1.1% | ||
| Q3 24 | -1.9% | 6.4% | ||
| Q2 24 | 2.6% | 12.2% | ||
| Q1 24 | 0.1% | 10.8% |
| Q4 25 | 4.0% | 3.5% | ||
| Q3 25 | 3.8% | 3.0% | ||
| Q2 25 | 4.8% | 3.9% | ||
| Q1 25 | 7.6% | 2.9% | ||
| Q4 24 | 6.7% | 3.7% | ||
| Q3 24 | 7.8% | 3.9% | ||
| Q2 24 | 7.1% | 3.6% | ||
| Q1 24 | 4.2% | 2.9% |
| Q4 25 | — | 9.70× | ||
| Q3 25 | — | 1.12× | ||
| Q2 25 | — | 2.25× | ||
| Q1 25 | — | 0.44× | ||
| Q4 24 | — | 10.57× | ||
| Q3 24 | — | 0.97× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 1.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
SXI
| Electronics Products Group | $115.7M | 52% |
| Engraving Services | $33.0M | 15% |
| Engineering Technologies Components | $30.6M | 14% |
| Transferred Over Time | $21.2M | 10% |
| Hydraulics Cylinders And System | $11.4M | 5% |
| Merchandising Display | $8.4M | 4% |
| Engraving Products | $2.7M | 1% |
